Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, with revenue of $5,295M (+0.69% vs. consensus) and Adjusted EPS of $1.13 (+9.08% vs. consensus). Growth was primarily driven by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS), which offset a 13.3% decline in Patient Care Solutions (PCS). Management reaffirmed FY26 guidance but signaled ongoing inflation headwinds of ~$250M, while record organic orders growth of 11.1% provides strong visibility for future quarters.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: GE HealthCare Tech(GEHC) the Revenue is 5.295 B (+5.75%), Beat estimate;the EBIT is 750 M (+2.88%), Beat estimate;the EPS is 1.24 (+16.98%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
5.29B5.75%
5.26B5.03%
+0.04B0.72%
EBITExceed expectations
0.75B2.88%
0.73B0.34%
+0.02B2.54%
EPSExceed expectations
1.2416.98%
0.937111.59%
+0.302928.57%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf